-
公开(公告)号：US07968286B2
公开(公告)日：2011-06-28
申请号：US12930661
申请日：2011-01-12
CPC分类号： C12N7/00 , A61K2039/5256 , C12N15/86 , C12N2710/10343 , C12N2740/15034 , C12N2760/18434 , C12Q1/702 , Y02A50/394 , Y02A50/412 , C12Q2563/131
摘要： Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
-
公开(公告)号：US20110150930A1
公开(公告)日：2011-06-23
申请号：US12928044
申请日：2010-12-01
IPC分类号： A61K39/235 , C12N15/63 , A61K31/7088 , A61P33/06 , A61P37/04
CPC分类号： C12N15/86 , A61K39/015 , A61K2039/5256 , C07K14/445 , C12N7/00 , C12N2710/10343 , Y02A50/412
摘要： Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.
摘要翻译： 描述了针对疟疾感染的疫苗，其基于重组病毒载体，例如α病毒，腺病毒或痘苗病毒。 基于重组病毒的疫苗可用于免疫不同的疟原虫感染，例如恶性疟原虫或约氏疟原虫的感染。 公开了密码子优化的环子孢子基因。 可以使用复制缺陷型腺病毒，其衍生自遇到低滴度中和抗体的血清型。 还描述了使用不同的腺病毒血清型，其被施用以引发强免疫应答，在单次疫苗接种装置或初始 - 加强装置中，其中可以应用基于不同血清型的组合物。
-
公开(公告)号：US07888096B2
公开(公告)日：2011-02-15
申请号：US11768796
申请日：2007-06-26
申请人： Zheng Wu , Shuyuan Zhang
发明人： Zheng Wu , Shuyuan Zhang
CPC分类号： C12N7/00 , A61K9/0019 , A61K9/19 , A61K35/761 , A61K47/02 , A61K47/183 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/38 , A61K47/42 , A61K47/46 , A61K48/00 , C12N15/86 , C12N2710/10051 , C12N2710/10332 , C12N2710/10343 , C12N2710/10351
摘要： The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
摘要翻译： 本发明解决了改善载体制剂的长期储存稳定性（即感染性）的需要。 特别地，已经证明，对于腺病毒，使用填充剂，冷冻保护剂和冻干保护剂赋予所需的性质，其允许冻干和液体腺病毒制剂在4℃下储存长达6个月并保持在60 -100％的起始传染性。
-
64.发明申请公开(公告)号：US20100041022A1
公开(公告)日：2010-02-18
申请号：US12587136
申请日：2009-10-02
IPC分类号： C12Q1/70
CPC分类号： C07K14/005 , A61K39/00 , C12N7/00 , C12N2760/16122 , C12N2760/16151 , C12N2760/16222 , C12N2760/16251 , C12N2760/16322 , C12N2760/16351 , G01N33/68 , G01N33/6842 , G01N2333/11 , G01N2333/12
摘要： Described are methods for separating hemagglutinin (HA) antigens, comprising the steps of applying a reduced and derivatized antigen preparation comprising solubilized HA antigens and a detergent in a pH controlled solution, on a Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) column; and eluting the HA antigens from the column with an ion pairing agent in an organic mobile phase. The invention further relates to quantifying methods using the methods for separating the antigens with the further step of measuring the peak area of the eluted antigen in a chromatogram resulting from the elution step.
摘要翻译： 描述了分离血凝素（HA）抗原的方法，包括以下步骤：在反相高效液相色谱（RP-HPLC）上，将包含溶解的HA抗原和洗涤剂的还原的和衍生的抗原制剂施用于pH控制的溶液中， 柱; 并用离子对试剂在有机流动相中从柱中洗脱HA抗原。 本发明还涉及使用分离抗原的方法的定量方法，其中进一步的步骤是在洗脱步骤得到的色谱图中测定洗脱抗原的峰面积。
-
65.发明授权公开(公告)号：US07537764B2
公开(公告)日：2009-05-26
申请号：US11511127
申请日：2006-08-28
CPC分类号： C07K16/1081 , A61K39/42 , A61K47/6839 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12N2770/24111 , G01N33/56983 , G01N2333/18 , G01N2469/10 , Y02A50/394 , Y02A50/60 , A61K2300/00
摘要： The invention provides human binding molecules specifically binding to West Nile virus and having West Nile virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, post-exposure prophylaxis and/or treatment of a condition resulting from West Nile virus.
摘要翻译： 本发明提供了特异性结合西尼罗病毒并具有西尼罗病毒中和活性的人结合分子，编码人结合分子的核酸分子，包含人结合分子的组合物以及鉴定或产生人结合分子的方法。 人结合分子可用于诊断，暴露后预防和/或治疗由西尼罗河病毒引起的病症。
-
公开(公告)号：US20090130652A1
公开(公告)日：2009-05-21
申请号：US11922405
申请日：2006-06-22
IPC分类号： C12Q1/70 , G01N33/567
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/005 , C07K2317/21 , C07K2317/76 , Y02A50/394
摘要： The invention relates to the production of binding molecules. In particular, the invention relates to methods for producing binding molecules having an improved functionality of interest.
摘要翻译： 本发明涉及结合分子的生产。 特别地，本发明涉及用于产生具有改进的感兴趣功能的结合分子的方法。
-
公开(公告)号：US07429486B2
公开(公告)日：2008-09-30
申请号：US11593279
申请日：2006-11-06
CPC分类号： C12P21/005 , A61K39/39558 , C07K16/00 , C07K16/10 , C07K16/2803 , C07K16/2833 , C07K16/2851 , C07K16/2896 , C07K16/30 , C07K16/32 , C07K2317/12 , C07K2317/21 , C07K2317/31 , C07K2317/50 , C07K2317/51 , C07K2317/56 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2319/30 , Y02P20/582
摘要： The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
摘要翻译： 本发明提供从单个宿主细胞克隆产生抗体混合物的方法，其中编码轻链的核酸序列和编码不同重链的核酸序列在重组宿主细胞中表达。 根据本发明的混合物中重组产生的抗体适当地包含与能够与轻链配对的不同重链配对的相同的轻链，从而形成功能性抗原结合结构域。 重组产生的抗体的混合物也由本发明提供。 这种混合物可用于各种领域。
-
68.发明申请Method for simultaneous production of multiple proteins; vectors and cells for use therein 有权同时生产多种蛋白质的方法 载体和细胞用于其中公开(公告)号：US20080227151A1
公开(公告)日：2008-09-18
申请号：US11978109
申请日：2007-10-26
CPC分类号： C07K16/00 , C07K16/18 , C12N15/67 , C12N15/8218 , C12N15/822 , C12N15/8257
摘要： Described is the production of proteins in a host cell. Even more specifically, described are methods for improving expression of two or more proteins in a cells or host cell. The methods are suited for production of, for example, recombinant antibodies that can be used in pharmaceutical preparations or as diagnostic tools. In certain embodiments, provided are methods for obtaining a cell that expresses two or more proteins comprising providing the cell with two or more protein expression units encoding two or more proteins, characterized in that at least two of the protein expression units comprise at least one STAR sequence.
摘要翻译： 描述了宿主细胞中蛋白质的产生。 更具体地，描述了用于改善细胞或宿主细胞中两种或更多种蛋白质的表达的方法。 该方法适用于生产例如可用于药物制剂或诊断工具的重组抗体。 在某些实施方案中，提供了获得表达两种或更多种蛋白质的细胞的方法，所述蛋白质包括向细胞提供编码两种或更多种蛋白质的两种或更多种蛋白质表达单位，其特征在于至少两种蛋白质表达单位包含至少一种STAR 序列。
-
公开(公告)号：US07425437B2
公开(公告)日：2008-09-16
申请号：US11110517
申请日：2005-04-20
CPC分类号： A61K39/12 , A61K2039/5252 , A61K2039/552 , A61K2039/55505 , A61K2039/55566 , C12N7/00 , C12N2770/24134 , C12N2770/24163
摘要： The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.
摘要翻译： 本发明涉及在人类细胞上产生的含有（全失活的）西尼罗病毒和/或由其衍生的西尼罗病毒蛋白质的新型疫苗，其中人细胞包含编码至少一个早期区域-1（E1）基因的序列 腺病毒的产物。 细胞优选在悬浮液中以非常高的密度和无血清条件培养。 在本文中，公开了使用这种细胞导致西尼罗病毒产生的高滴度。
-
公开(公告)号：US20080199433A1
公开(公告)日：2008-08-21
申请号：US11786409
申请日：2007-04-11
CPC分类号： C12N15/86 , C12N7/00 , C12N7/025 , C12N15/861 , C12N2710/10041 , C12N2710/10051 , C12N2710/10343 , C12N2710/10352 , C12N2830/00 , C12N2840/20
摘要： A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. Also, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, and measles virus.
-
-
-
-
-
-
-
-
-
搜索结果
249 条记录 (耗时 0.06 秒)
